SYNLAB and Microba Life Sciences have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.
Responding to the success on the Spanish and Colombian markets and the growing demand for personalised precision diagnostics, the test will be rolled out for further distribution via healthcare providers as well as direct-to-consumer channels.
“Imbalances in the gut microbiome composition, distribution and activity have a direct health impact and are associated with chronic illness including gastrointestinal, inflammatory, metabolic, neurological and cardiovascular conditions,” says Michael Morris, Head of Genetics at SYNLAB Switzerland. “myBIOME is the most complete and accurate metagenomic sequencing test available on the market today, allowing for a comprehensive, highly differentiated and actionable analysis of an individual’s gut microbiome.”
Through next-generation sequencing (NGS), myBIOME analyses all the genetic material (DNA) in a stool sample, allowing a highly sensitive, high-resolution panel of the microorganisms that make it up.
Applying game-changing metagenomic technology developed by Microba, myBIOME detects all types of microorganisms (bacteria, archaea, fungi, protists), identifies the exact species and characterises new species. Based on the functional potential determined by analysing the microbial genes present, the test report delivers a personalised analysis and nutritional recommendations to improve patient health and quality of life.
“SYNLAB is committed to offering medical excellence around the globe and I am excited that now, more customers and patients will benefit from this reliable tool,” says Marta Llopis, myBIOME/ Microbiome Specialist at SYNLAB Group. “In many cases, myBIOME has pinpointed the origin of a variety of diffuse symptoms by linking them to a microbiome imbalance or for example an excessive presence of non-intestinal species. When found at high levels in the gut, these have been shown to cause disease.”
SYNLAB performed around 600 million laboratory tests and achieved revenues of €3.76 billion in 2021. More information on the company can be found at www.synlab.com.
Microba Life Sciences is a precision microbiome company driven to improve human health. More information on myBIOME can be found at www.mybiome.health.
